Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
6(85.7%)
Phase 2
1(14.3%)
7Total
Phase 1(6)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06887803Phase 1Recruiting

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

Role: lead

NCT05586516Phase 1Completed

A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer

Role: lead

NCT04328844Phase 1Active Not Recruiting

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Role: lead

NCT07018752Phase 1Recruiting

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

Role: collaborator

NCT06717126Phase 2Active Not Recruiting

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

Role: lead

NCT06879717Phase 1Active Not Recruiting

A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients

Role: lead

NCT05027568Phase 1Completed

A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers

Role: lead

All 7 trials loaded